← All trials
NCT07118176
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2025
- Primary completion
- Sep 6, 2026
- Completion date
- Sep 7, 2027
- First posted
- Aug 12, 2025
- Last posted
- Aug 12, 2025
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, Los AngelesLead sponsor
- University of California, Los AngelesOfficial
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Adrenal Gland Neoplasms
- Urinary Bladder Neoplasms
- Brain Neoplasms
- Breast Neoplasms
- Carcinoma, Transitional Cell
- Uterine Cervical Neoplasms
- Esophageal Neoplasms
- Hamartoma
- Carcinoma, Hepatocellular
- Lung Neoplasms
- Lymphoma
- Neoplasm Metastasis
- Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Penile Neoplasms
- Pleural Neoplasms
- Prostatic Neoplasms
- Rectal Neoplasms
- Salivary Gland Neoplasms
- Sarcoma
- Skin Neoplasms
- Stomach Neoplasms
- Testicular Neoplasms
- Thyroid Neoplasms
- Vaginal Neoplasms
- Colorectal Neoplasms
- Cholangiocarcinoma
- Solitary Fibrous Tumors
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.